EUVIMEDEUVIMED entdecken
Crossref

Fusion‐targeted biopsy significantly improves prostate cancer detection in biopsy‐naïve men

Leandro Blas iD, Masaki Shiota iD, Shigehiro Tsukahara, Shunsuke Goto, Fumio Kinoshita, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi iD, Masatoshi Eto

International Journal of Urology · 2023

DOI: 10.1111/iju.15188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2023. Verfasst von Leandro Blas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The precise diagnosis of prostate cancer (PC) is crucial to avoid underdiagnosis, overdiagnosis, and overtreatment. We aimed to compare clinically significant PC (csPC) detection between MRI/ultrasound fusion‐targeted prostate (TBx) compared to systematic biopsy (SBx) in biopsy‐naïve Japanese men.

Methods

We included patients with suspect PC due to elevated PSA level or abnormal digital rectal examination, or both. csPC was defined as International Society Urological Pathology (ISUP) grade group ≥2 (csPC‐A) and ISUP grade group ≥3 (csPC‐B).

Results

This study included 143 patients. Overall PC detection was 66.4% for SBx and 67.8% for MRI‐TBx. MRI‐TBx presented a significantly higher rate of csPC detection (csPC‐A 67.1% vs. 58.7%, p = 0.04, and csPC‐B 49.6% vs. 39.9%, p < 0.001) and significantly lower detection of non‐csPC‐A (0.6% vs. 6.7%). Importantly, MRI‐TBx missed 4.9% (7/143) of csPC‐A and only 0.7% (1/143) of csPC‐B. On the other hand, SBx alone missed 13.3% (19/143) of csPC‐A and 4.2% (6/143) of csPC‐B.

Conclusion

MRI‐TBx significantly outperformed 12‐cores SBx for csPC detection and decreased non‐csPC detection in biopsy‐naive men. Performing MRI‐TBx without SBx would have missed some csPC, supporting that MRI‐TBx synergizes with SBx to increase csPC detection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansBiopsyImage-Guided BiopsyMagnetic Resonance ImagingPelvisRetrospective Studies

Stichwörter der Autor:innen

MRIbiopsy-naïvefusion prostate biopsyprostatic neoplasm

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

ORCID-Profile: Leandro Blas, Masaki Shiota, Junichi Inokuchi

Zitieren

APA

Blas, L., Shiota, M., Tsukahara, S., Goto, S., Kinoshita, F., Matsumoto, T., Monji, K., Kashiwagi, E., Inokuchi, J., & Eto, M. (2023). Fusion‐targeted biopsy significantly improves prostate cancer detection in biopsy‐naïve men. International Journal of Urology. https://doi.org/10.1111/iju.15188

Vancouver

Blas L, Shiota M, Tsukahara S, Goto S, Kinoshita F, Matsumoto T, et al. Fusion‐targeted biopsy significantly improves prostate cancer detection in biopsy‐naïve men. International Journal of Urology. 2023. doi:10.1111/iju.15188

BibTeX
@article{Blas2023,
  author = {Blas, Leandro and Shiota, Masaki and Tsukahara, Shigehiro and Goto, Shunsuke and Kinoshita, Fumio and Matsumoto, Takashi and Monji, Keisuke and Kashiwagi, Eiji and Inokuchi, Junichi and Eto, Masatoshi},
  title = {Fusion‐targeted biopsy significantly improves prostate cancer detection in biopsy‐naïve men},
  journal = {International Journal of Urology},
  year = {2023},
  doi = {10.1111/iju.15188}
}
Kostenlos starten →